FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

Why it matters locally: This FDA approval is significant for Oklahomans with sickle cell disease and transfusion-dependent beta thalassemia, especially young children, as it expands access to a new treatment option that could profoundly improve their quality of life. Access to this advanced therapy in the state will depend on availability at local medical centers and insurance coverage.

---

The U.S. Food and Drug Administration (FDA) today announced a supplemental approval for Casgevy (exagamglogene autotemcel). This expanded approval permits the use of the gene therapy for patients aged two years and older. The therapy is indicated for individuals diagnosed with sickle cell disease (SCD) who experience recurrent vaso-occlusive crises (VOCs). Additionally, the approval covers patients with transfusion-dependent beta thalassemia (TDT).